Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors
about
A genome-wide association study of carotid atherosclerosis in HIV-infected menLipoprotein particle subclasses, cardiovascular disease and HIV infection.Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial.Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE)Exploration of the Effect of Tobacco Smoking on Metabolic Measures in Young People Living with HIVObesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021.Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice.HIV protease inhibitors and obesityBaseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialPreclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study.Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thicknessRegional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophyIntermuscular adipose tissue and metabolic associations in HIV infectionShortcuts to a functional adipose tissue: The role of small non-coding RNAs.Diabetes in HIV-infected persons in Cameroon?CHA2DS2-VASc Score, Warfarin Use, and Risk for Thromboembolic Events Among HIV-Infected Persons With Atrial Fibrillation.The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir.Early atherosclerosis in HIV-infected patients below the age of 55 years: Slovenian national study.Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.Randomized trial to evaluate cardiometabolic and endothelial function in patients with plasma HIV-1 RNA suppression switching to darunavir/ritonavir with or without nucleoside analogues.Markers of microbial translocation predict hypertension in HIV-infected individuals.Left ventricular remodelling in asymptomatic HIV infection on chronic HAART: comparison between hypertensive and normotensive subjects with and without HIV infection.HIV Infection, Antiretroviral Therapy and Cardiovascular Risk.Metabolic and Cardiac Adaptation to Chronic Pharmacologic Blockade of Facilitative Glucose Transport in Murine Dilated Cardiomyopathy and Myocardial Ischemia.From lipodystrophy to cardiovascular disease: new insight into the management of HIV infection
P2860
Q24622468-DD0E83C8-CB3B-4377-B4AE-EC4308725D58Q33639078-A8205E1B-536D-420F-95C4-8B8E28743632Q33759853-5C046323-B69D-4518-9A3C-6C740CE4E237Q33944936-1721D2C8-C7C1-416B-ADDE-140538AAC19DQ33993939-1B52892F-709E-4E5A-94AF-23915380CCF4Q34129180-D43030B3-49F0-45B4-A650-BEFBBB34E68EQ34299021-511FE383-5D43-47DB-94B5-D4F9424F7D5CQ34792983-035550D5-52A2-4E3B-8F65-EFB02EF3D812Q35124939-0D64800D-7F05-488C-ADE7-D559C682D211Q35166149-989A3405-6C28-490E-9917-03D33007E2FFQ35574115-8DD54999-2CFC-470D-B8A7-D4A5E3417227Q35844759-7E8C60F5-C865-47C6-B328-0220AFAC99BBQ37063431-C07963EE-3E66-4ADC-9EE2-82A1EA621502Q37645670-8B5FE439-15E3-4158-ACB6-EE854B586746Q38900754-8C0365F9-43FF-41CD-A115-9A427F065B0BQ40098541-AE2702DD-927E-4B03-8B2A-D97D0440DE1EQ41066112-1E3C3775-4815-4E61-8118-D7CF2757A66CQ42230026-AB13D397-1802-451B-A03C-C4E07FA3A1ECQ42241185-CB966A34-DC2C-4189-B2CF-354A1FECE203Q42278370-8B076126-8EC7-4B71-B845-70800F6E5747Q46638257-E397B357-ECE8-42D8-AD2E-FD7FA61F0519Q51368199-7E37F1E8-3945-401E-835A-142819E544DEQ55210420-DC80E88E-3505-4A6C-B42A-3D6A6F598734Q55363508-D8E36830-F582-437E-B76A-A72E10C9A454Q58798012-86E97E77-4963-47C9-B70D-EB80580C803A
P2860
Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Contribution of metabolic and ...... ovascular disease risk factors
@ast
Contribution of metabolic and ...... ovascular disease risk factors
@en
type
label
Contribution of metabolic and ...... ovascular disease risk factors
@ast
Contribution of metabolic and ...... ovascular disease risk factors
@en
prefLabel
Contribution of metabolic and ...... ovascular disease risk factors
@ast
Contribution of metabolic and ...... ovascular disease risk factors
@en
P2093
P2860
P1433
P1476
Contribution of metabolic and ...... ovascular disease risk factors
@en
P2093
Carl Grunfeld
Donald P Kotler
Henry Masur
Julian M Falutz
Katherine Samaras
Kathleen Mulligan
Peter Reiss
Steven M Haffner
Working Group 1
P2860
P356
10.1161/CIRCULATIONAHA.107.189623
P407
P577
2008-06-19T00:00:00Z